Pilot study of topical delivery on mono-L-aspartyl chlorin e6 (NPe6): Implication of topical NPe6-photodynamic therapy

Journal of Pharmacological Sciences

Volumn 93, Issue 2, 2003, Pages 136-142

  Wong, Tak Wah ^a   Aizawa, Katsuo ^b   Sheyhedin, Ilyar ^b   Wushur, ChiMenGul ^b   Kato, Harubumi ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Mono L aspartyl chlorin e6 (NPe6); Topical delivery; Topical photodynamic therapy

Indexed keywords

TALAPORFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CELL DISRUPTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMIS; DOSE CALCULATION; DOSE RESPONSE; DRUG PENETRATION; DRUG TISSUE LEVEL; EPIDERMIS; FEMALE; FLUORESCENCE MICROSCOPY; FREEZING; MOUSE; MOUSE STRAIN; NONHUMAN; PHOTODYNAMIC THERAPY; PILOT STUDY; SKIN CANCER; SKIN PENETRATION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TEST STRIP;

ADMINISTRATION, TOPICAL; ANIMALS; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; SKIN; SKIN ABSORPTION;

EID: 0242636335     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.93.136     Document Type: Article

References (21)

1. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997;79:2282-2308.
2. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol. 2000;42:389-413.
3. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy. A new method for the treatment of malignant tumors. Cancer Res. 1978;38:2628-2635.
4. Rick K, Sroka R, Stepp H, et al. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. J Photochem Photobiol B. 1997;40:313-319.
5. Spikes JD, Bommer JC. Photosensitizing properties of mono-L-aspartyl chlorin e6 (NPe6): A candidate sensitizer for the photodynamic therapy of tumors. J Photochem Photobiol B. 1993;17:135-143.
6. Roberts WG, Berns MW. In vitro photosensitization I. Cellular uptake and subcellular localization of mono-L-aspartyl chlorin e6, chloro-aluminum sulfonated phthalocyanine, and photofrin II. Lasers Surg Med. 1989;9:90-101.
7. Kessel D. Determinants of photosensitization by mono-L-aspartyl chlorin e6. Photochem Photobiol. 1989;49:447-452.
8. Roberts WG, Liaw LH, Berns MW. In vitro photosensitization II. An electron microscopy study of cellular destruction with mono-L-aspartyl chlorin e6 and photofrin II. Lasers Surg Med. 1989;9:102-108.
9. Kessel D. Sites of photosensitization by derivatives of hematoporphyrin. Photochem Photobiol. 1986;44:489-494.
10. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst. 1988;80:1599-1605.
11. Wong KSLM, Wang KK, Zinsmeister AR. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer. 1998;82:421-427.
12. Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (NPe6) for the treatment of cutaneous disease: A phase I clinical study. Clin Cancer Res. 1998;4:2741-2746.
13. Sheyhedin I, Aizawa K, Araake M, Kumasaka H, Okunaka T, Kato H. The effect of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro. Photochem Photobiol. 1998;68:110-114.
14. Sheyhedin I, Okunaka T, Kato H, et al. Localization of experimental submucosal esophageal tumor in rabbits using mono-L-aspartyl chlorin e6 and long wavelength photodynamic excitation. Lasers Surg Med. 2000;26:83-89.
15. Nelson JS, Roberts WG, Berns MW. In vivo studies on the utilization of mono-L-aspartyl chlorin e6 (NPe6) for photodynamic therapy. Cancer Res. 1987;47:4681-4685.
16. Katsumi TA, Aizawa K, Kuroiwa Y, et al. Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin e6. Photochem Photobiol. 1996;64:671-675.
17. Allen RP, Kessel D, Tharratt RS, Volz W. Photodynamic therapy of superficial malignancies with NPe6 in man. In: P Spinelli, M Dal Fante, R Marchesini, editors. Photodynamic Therapy and Biomedical Lasers. New York: Elsevier Science; 1992. p. 441-445.
18. Tsai JC, Chen IH, Wong TW, Lo YL. In vitro/in vivo correlations between transdermal delivery of 5-aminolevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation. Br J Dermatol. 2002;146:853-862.
19. Hayashi J, Saito T, Sato H, Kuroiwa Y, Aizawa K. Direct visualization of the atherosclerosis in small coronary arteries using the epifluorescence steroscope. Cardiovas Res. 1995;30:775-780.
20. Lever W, Schaumburg-Lever G. Histopathology of the Skin. 7th ed. Philadelphia: JB Lippincott; 1990. p. 542-546; p. 549-560; p. 622-634.
21. Wong TW, Sheu HM, Lee JYY, Fletcher RJ. Photodynamic therapy for Bowen's disease (squamous cell carcinoma in situ) of the digit. Dermatol Surg. 2001;27:452-456.